Currently, there are three biomarkers, which have been approved by the FDA as predictive biomarkers: PD-L1 expression on tumor cells, microsatellite instability/defective mismatch repair (MSI/dMMR), and tumor mutational burden (TMB), indicated in Table 2 [17,18,19]. The gene discussed is CD274; the disease is neoplasm.